Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma
Brief Summary: RATIONALE: Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also block the growth of the tumor by blocking blood flow to the tumor. It is not yet known whether bevacizumab together with dasatinib are more effective than a placebo in treating patients with recurrent or progressive high-grade glioma or glioblastoma multiforme.

PURPOSE: This randomized phase I/II trial (Phase I completed) is studying the side effects and best dose of dasatinib when given together with bevacizumab and to see how well it works compared to placebo in treating patients with recurrent or progressive high-grade glioma or glioblastoma multiforme.


Options:
A: Arm Label: Group A: DNX-2401; Type: EXPERIMENTAL; Interventions: Drug: DNX-2401 | Arm Label: Group B: DNX-2401 + Surgery; Type: EXPERIMENTAL; Interventions: Drug: DNX-2401, Procedure: Tumor Removal | Intervention Type: DRUG; Name: DNX-2401; Assigned to Arm(s): Group A: DNX-2401, Group B: DNX-2401 + Surgery | Intervention Type: PROCEDURE; Name: Tumor Removal; Assigned to Arm(s): Group B: DNX-2401 + Surgery
B: Arm Label: Arm I; Type: EXPERIMENTAL; Interventions: Biological: bevacizumab, Drug: dasatinib | Arm Label: Arm II; Type: ACTIVE_COMPARATOR; Interventions: Biological: bevacizumab, Other: placebo | Intervention Type: BIOLOGICAL; Name: bevacizumab; Assigned to Arm(s): Arm I, Arm II | Intervention Type: DRUG; Name: dasatinib; Assigned to Arm(s): Arm I | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Arm II
C: Arm Label: LY2157299 monohydrate plus lomustine; Type: EXPERIMENTAL; Interventions: Drug: LY2157299 monohydrate, Drug: Lomustine | Arm Label: LY2157299 monohydrate; Type: EXPERIMENTAL; Interventions: Drug: LY2157299 monohydrate | Arm Label: lomustine plus placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lomustine, Drug: Placebo | Intervention Type: DRUG; Name: LY2157299 monohydrate; Assigned to Arm(s): LY2157299 monohydrate, LY2157299 monohydrate plus lomustine | Intervention Type: DRUG; Name: Lomustine; Assigned to Arm(s): LY2157299 monohydrate plus lomustine, lomustine plus placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): lomustine plus placebo
D: Arm Label: Temozolomide; Type: ACTIVE_COMPARATOR; Interventions: Drug: temozolomide, Genetic: DNA methylation analysis, Procedure: quality-of-life assessment | Arm Label: Radiation; Type: ACTIVE_COMPARATOR; Interventions: Genetic: DNA methylation analysis, Procedure: quality-of-life assessment, Radiation: Radiation | Intervention Type: DRUG; Name: temozolomide; Assigned to Arm(s): Temozolomide | Intervention Type: GENETIC; Name: DNA methylation analysis; Assigned to Arm(s): Radiation, Temozolomide | Intervention Type: PROCEDURE; Name: quality-of-life assessment; Assigned to Arm(s): Radiation, Temozolomide | Intervention Type: RADIATION; Name: Radiation; Assigned to Arm(s): Radiation

Answer: B